BUY Krishna Institute of Medical Sciences Limited — Kshitija Salvi, Globe Capital Market
byKshitija Salvi, Globe Capital MarketHorizon: NA (inferred Swing (≤2wk))30 Jul 2026via CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
Alembic Pharma, KIMS Get Target Price Hikes After Q1, Latent View Sees Downgrade: ICICI Securities
NewsNdtv-Profit·5 Aug · 1w ago
Indian Pharma Q1 FY27 Deals: సన్ ఫార్మా అద్భుతంతో **$13.9 బిలియన్** విలువ నమోదు
NewsGoogle News·23 Jul · 3w ago
सन फार्माच्या डीलमुळे भारतीय फार्मा सेक्टरमध्ये ₹13.9 बिलियनचा व्यवहार; विशेष पोर्टफोलिओवर भर
NewsGoogle News·23 Jul · 3w ago
1 advisor has an active short-term BUY call on this stock
Advisor consensus · adjacent horizon·9 Jun · 2mo ago
Krishna Institute of Medical Sciences Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported total revenue of INR 1,196 Cr, a growth of 36.1% YoY
BSE · Company Update·3 Aug · 1w ago
Krishna Institute of Medical Sciences Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The results will be available on the company's website.
NSE · Press Release·3 Aug · 1w ago
Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·3 Aug · 1w ago
KIMS Shares Trade Near ₹780 Support Level
NewsGoogle News·27 Jul · 2w ago
KIMS Share Price: ₹780 च्या सपोर्ट लेव्हलवर!
NewsGoogle News·27 Jul · 2w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Krishna Institute of Medical Sciences
- BUY — Jigar S Patel, Anand Rathi19 Oct 2026 · ~3 months · target ₹800 · Active
- BUY — HSBC Securities9 Oct 2026 · ~1 year · target ₹865 · Active
- BUY — Goldman Sachs1 Oct 2026 · ~1 year · target ₹1,000 · Active
- BUY — Emkay Global1 Oct 2026 · ~1 year · target ₹850 · Active
- BUY — Rakesh Bansal24 Sept 2026 · ~2 weeks · target ₹831 · SL hit
More from Kshitija Salvi, Globe Capital Market
- BUY Laurus Labs11 Sept 2026 · ~2 weeks · target ₹2,140 · SL hit
- BUY Ather Energy10 Sept 2026 · ~2 weeks · target ₹1,760 · SL hit
- BUY Cholamandalam Investment and Finance Company10 Sept 2026 · ~2 weeks · target ₹1,985 · SL hit
- BUY Adani Ports and Special Economic Zone9 Sept 2026 · ~2 weeks · target ₹1,900 · Expired
- BUY Ajanta Pharma8 Sept 2026 · ~2 weeks · target ₹3,825 · SL hit

